What are the indications for dual antiplatelet therapy (aspirin plus clopidogrel) in patients with stroke?

Indications for Dual Antiplatelet Therapy (DAPT) in Stroke

Dual antiplatelet therapy with aspirin plus clopidogrel is indicated for patients with minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 score ≥4) of non-cardioembolic origin, initiated within 24 hours of symptom onset and continued for 21-30 days, followed by single antiplatelet therapy. 1

Primary Indication: Minor Stroke and High-Risk TIA

The most robust evidence supports DAPT in a specific, well-defined population:

• Patient criteria: Minor ischemic stroke with NIHSS score ≤3 OR high-risk TIA with ABCD2 score ≥4
• Stroke type: Non-cardioembolic origin only
• Timing: Must be initiated within 24 hours of symptom onset (ideally within 12 hours) 2
• Duration: 21-30 days only, then transition to single antiplatelet therapy 2

Dosing Regimen

Loading doses 2:

• Aspirin: 160-325 mg
• Clopidogrel: 300-600 mg (300 mg based on CHANCE trial, 600 mg based on POINT trial)

Maintenance doses:

• Aspirin: 81 mg daily
• Clopidogrel: 75 mg daily

The evidence supporting this comes from the CHANCE and POINT trials, which demonstrated that for every 1000 patients treated with DAPT for 90 days, 15 ischemic strokes would be prevented but 5 major hemorrhages would result. This risk-benefit profile led to the recommendation limiting DAPT to 21-30 days rather than 90 days 2.

Alternative DAPT Regimen: Aspirin Plus Ticagrelor

For patients with mild-moderate stroke (NIHSS ≤5) or high-risk TIA (ABCD2 ≥4), aspirin plus ticagrelor may be considered for 30 days 1:

• Loading doses: Aspirin 300-325 mg + Ticagrelor 180 mg
• Maintenance: Aspirin 75-100 mg daily + Ticagrelor 90 mg twice daily
• Duration: 30 days, followed by single antiplatelet therapy

This regimen may be particularly useful in patients with CYP2C19 genetic polymorphisms causing clopidogrel resistance 3.

Additional Indication: Symptomatic Intracranial Atherosclerosis

In patients with moderate-to-high-grade intracranial atherosclerotic stenosis (50-99%), DAPT is appropriate medical therapy 1. This should be combined with:

• Systolic blood pressure target <140 mmHg
• High-dose statin therapy
• At least moderate physical activity

Critical Exclusions and Contraindications

Do NOT use DAPT in the following situations 2, 4:

1. After thrombolysis (alteplase): Delay antiplatelet initiation until 24-hour post-thrombolysis scan excludes intracranial hemorrhage 2
2. Moderate-to-severe stroke: DAPT benefit is limited to minor strokes (NIHSS ≤3-5)
3. Cardioembolic stroke: These patients require anticoagulation, not DAPT
4. Active bleeding or high bleeding risk: Contraindicated with active pathological bleeding 5
5. Beyond 24 hours of symptom onset: The window for initiating DAPT closes rapidly

Important Clinical Considerations

Timing is Critical

• Start before ED discharge 2
• Brain imaging must exclude intracranial hemorrhage first
• Dysphagia screening must be performed and passed before oral administration

Duration Matters for Safety

Long-term DAPT (>90 days) is associated with excess hemorrhage risk without additional benefit 6, 7. The MATCH and SPS3 trials demonstrated no benefit of prolonged DAPT compared to single antiplatelet therapy, with significantly increased major bleeding 7.

Special Populations

Patients with dysphagia 2:

• Aspirin 80 mg daily and clopidogrel 75 mg daily via enteral tube, OR
• Aspirin 325 mg daily via rectal suppository

Patients requiring urgent carotid intervention: Consider aspirin monotherapy rather than DAPT if urgent carotid endarterectomy is planned, to reduce perioperative bleeding risk 2.

Gastrointestinal Protection

Consider GI protection in patients at higher risk of GI bleeding, though extracranial bleeding events remain relatively low (0.9% with DAPT vs 0.4% with monotherapy in POINT trial) 2.

Common Pitfalls to Avoid

1. Using DAPT for too long: The benefit is confined to the first 21-30 days; continuing beyond this increases bleeding risk without additional benefit 8
2. Starting DAPT in moderate-severe stroke: No evidence of benefit in NIHSS >3-5
3. Forgetting to transition to monotherapy: Patients must be counseled that DAPT is temporary 2
4. Using DAPT with omeprazole/esomeprazole: These significantly reduce clopidogrel's antiplatelet activity; use alternative PPIs if needed 5